What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
Lorenz C. Hofbauer mainly investigates Internal medicine, Endocrinology, Osteoprotegerin, Osteoporosis and Bone remodeling.
His study looks at the relationship between Internal medicine and fields such as Diabetes mellitus, as well as how they intersect with chemical problems.
His Endocrinology research incorporates themes from Calcification, RANK Ligand and Osteoblast.
The concepts of his Osteoprotegerin study are interwoven with issues in Osteoclast, Cytokine, Bone resorption and RANKL.
Lorenz C. Hofbauer studied RANKL and Bone disease that intersect with Bone marrow and Lesion.
The study incorporates disciplines such as Vitamin D and neurology and Pharmacotherapy in addition to Osteoporosis.
His most cited work include:
- Osteoporosis: now and the future (1286 citations)
- Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases (793 citations)
- Romosozumab Treatment in Postmenopausal Women with Osteoporosis. (537 citations)
What are the main themes of his work throughout his whole career to date?
Lorenz C. Hofbauer spends much of his time researching Internal medicine, Endocrinology, Cancer research, Bone remodeling and Osteoporosis.
His Internal medicine study often links to related topics such as Oncology.
Lorenz C. Hofbauer combines subjects such as Sclerostin, Receptor and Osteoblast with his study of Endocrinology.
The Cancer research study combines topics in areas such as Haematopoiesis, Immunology, Bone marrow, Breast cancer and Prostate cancer.
His Bone remodeling study integrates concerns from other disciplines, such as Osteocalcin, Bone density and Cortical bone.
His research in Osteoporosis intersects with topics in Vitamin D and neurology and Surgery.
He most often published in these fields:
- Internal medicine (61.02%)
- Endocrinology (46.73%)
- Cancer research (26.88%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (61.02%)
- Endocrinology (46.73%)
- Cancer research (26.88%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Endocrinology, Cancer research, Bone remodeling and Osteoporosis.
His Internal medicine study combines topics from a wide range of disciplines, such as Sclerostin and Oncology.
Lorenz C. Hofbauer interconnects Cortical bone, Wnt signaling pathway, DKK1 and Osteoblast in the investigation of issues within Endocrinology.
His study in Cancer research is interdisciplinary in nature, drawing from both Haematopoiesis, Receptor, Bone metastasis, Prostate cancer and Bone marrow.
His work on Teriparatide is typically connected to Placebo as part of general Osteoporosis study, connecting several disciplines of science.
His studies in RANKL integrate themes in fields like Osteoprotegerin and Adverse effect.
Between 2017 and 2021, his most popular works were:
- Thy-1 (CD90) Promotes Bone Formation and Protects Against Obesity (37 citations)
- Bone health during endocrine therapy for cancer (32 citations)
- Bone health during endocrine therapy for cancer (32 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
Internal medicine, Bone remodeling, Osteoporosis, Endocrinology and Cancer research are his primary areas of study.
His Internal medicine research is multidisciplinary, incorporating elements of Sclerostin and Oncology.
His Bone remodeling research incorporates themes from Glucose uptake, Physiology and Endocrine system.
His work in the fields of Denosumab, Teriparatide and Bone mineral overlaps with other areas such as Context and Likert scale.
His Endocrinology research includes themes of DKK1 and Osteoblast.
The Cancer research study combines topics in areas such as Statin, Apoptosis, Cancer cell, Receptor and Bone marrow.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
